Business Context and Reporting Period
This Form 8-K was filed by Galectin Therapeutics Inc. on December 20, 2011. The report addresses a specific event regarding a previously filed document rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report focused on a contractual disclosure update and does not contain financial statement data.
Material Changes
The primary material change disclosed is the restoration of redacted information in a previously filed agreement:
- Document: Collaboration, Supply, Marketing and Distribution Agreement with Procaps S.A. (dated October 18, 2011).
- Previous Filing: Exhibit 10.2 to the Form 10-Q filed on November 10, 2011, contained redactions regarding the term of the Agreement due to a request for confidential treatment.
- Current Action: This filing provides the same agreement with the information regarding the term of the Agreement restored in Section 18.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. The only noted contingency is the prior application for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, which has now been resolved for the specific term details.
Investor Verification Checklist
- Verify the specific term of the Agreement with Procaps S.A. now disclosed in Section 18 of the attached Exhibit 10.2.
- Review the original redacted Exhibit 10.2 from the November 10, 2011 Form 10-Q to understand the scope of the previously withheld information.
- Confirm the status of the collaboration with Procaps S.A. in subsequent filings to assess commercial progress.